Answers are grounded in this paper and cite their sources.
Global elimination of hepatitis B virus (HBV) requires scale-up of testing and treatment services in low-income and middle-income countries (LMICs). Following the screening for hepatitis B surface antigen (HBsAg), quantification of serum HBV DNA is invariably required to identify a subset of HBV-infected individuals who should immediately start antiviral therapy. Anti-HBV treatment is recommended for patients with chronic HBV infection (CHB) who have high HBV DNA levels (≥2000 or ≥20,000 IU/mL) in the presence of liver fibrosis or inflamation.
No takes yet. Share an insight, caveat, or question.
Shimakawa et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: